Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 4 Interventional Results available

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

NCT01873417
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BG00012 (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
37
States / cities
Cullman, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 18, 2026, 7:35 PM EDT
Active, not recruiting Not applicable Interventional

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

NCT04865679
View directory record Official record
Conditions
Symptomatic Neuroma, Amputation, Chronic Nerve Pain
Interventions
Axoguard Nerve Cap®
Device
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

NCT02891915
View directory record Official record
Conditions
Pneumonia
Interventions
Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 71 Months
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 18, 2026, 7:35 PM EDT
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release

NCT00994383
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

NCT04994769
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Epitomee Capsule
Device
Lead sponsor
Epitomee medical
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

NCT03712241
View directory record Official record
Conditions
Healthy
Interventions
K-285, Indomethacin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

NCT02616302
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions

NCT01107353
View directory record Official record
Conditions
Depression
Interventions
Imipramine Pamoate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 18, 2026, 7:35 PM EDT
Completed No phase listed Observational

Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)

NCT00555737
View directory record Official record
Conditions
Celiac Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

NCT03247556
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 400mg SPN-812, 600mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Not applicable Interventional Results available

Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation

NCT02107157
View directory record Official record
Conditions
Facial Rejuvenation
Interventions
755nm Laser with Cap Array
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

NCT02359045
View directory record Official record
Conditions
Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions
D1400147, D14000136, D14000137, Epanova®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293
View directory record Official record
Conditions
Homeostasis, Bone and Bones
Interventions
Dexlansoprazole, Esomeprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 75 Years · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Early Phase 1 Interventional

Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression

NCT00555698
View directory record Official record
Conditions
Depression
Interventions
Deep Brain Stimulations for Depression
Device
Lead sponsor
Ali Rezai, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

NCT04856293
View directory record Official record
Conditions
Healthy Participants
Interventions
Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Not applicable Interventional

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

NCT00000892
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 4 Interventional

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

NCT00106821
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide Inhalation Powder
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

NCT02136914
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
Interventions
ADS-5102, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 18, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

NCT00865215
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 18, 2026, 7:35 PM EDT